Peer-reviewed
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C Munshi, Larry D Anderson, Nina Shah, Deepu Madduri, Jesús Berdeja, Sagar Lonial, Noopur Raje, Yi Lin, David Siegel, Albert Oriol, Philippe Moreau, Ibrahim Yakoub-Agha, Michel Delforge, Michele Cavo, Hermann Einsele, Hartmut Goldschmidt, Katja Weisel, Alessandro Rambaldi, Donna Reece, Fabio Petrocca, Monica Massaro, Jamie N Connarn, Shari Kaiser, Payal Patel, Liping Huang, Timothy B Campbell, Kristen Hege, Jesús San-Miguel
Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma
Article, 2021